Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
Would you consider consolidative RT in patients with metastatic bladder cancer after near complete response after Keytruda?
Answer from: Radiation Oncologist at Community Practice
Generally, no I wouldn't, as I can't quantify the risk-to-benefit ratio given the paucity of data.
Sign In
or
Register
to read more
20304
Related Questions
How do you approach ADT in patients with high-risk prostate cancer who have risk factors for VTE, such as Factor V Leiden?
Do you recommend neoadjuvant 177Lu-PNT2002 followed by MDT per the LUNAR trial as your preferred treatment approach for oligorecurrent prostate cancer, as opposed to MDT and PSMA-radioligand therapy used as temporally separate treatments?
Do you utilize daily enemas for patients undergoing prostate SBRT?
What dose/fractionation would you recommend for a prostate patient who previously received 1 of 5 planned fractions SBRT in 2020?
How does the presence of indeterminate lymphadenopathy on PSMA PET scan alter your management of unfavorable intermediate-risk prostate cancer?
What are your top takeaways from ASCO GU 2025?
Would you continue serial PSMA PET scans after 2 negative scans for patients with a persistently rising PSA post-RT?
How do you design pelvic lymph node treatment volumes for patients with tortuous or aberrant vascular anatomy?
Can a PSA bounce be seen shortly after SBRT to prostate cancer oligometastases while on androgen deprivation therapy?
Are there any scenarios in which you would offer SBRT as your preferred treatment approach for appropriate candidates with intermediate risk prostate cancer?